CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade DarioHealth Corp. - DRIO CFD

    1.12
    5.88%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    DarioHealth Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.19
    Open* 1.21
    1-Year Change* -65.43%
    Day's Range* 1.1 - 1.21
    52 wk Range 0.68-6.22
    Average Volume (10 days) 186.51K
    Average Volume (3 months) 4.29M
    Market Cap 67.22M
    P/E Ratio -100.00K
    Shares Outstanding 27.21M
    Revenue 23.55M
    EPS -2.20
    Dividend (Yield %) N/A
    Beta 1.67
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 18, 2024 1.12 -0.09 -7.44% 1.21 1.21 1.10
    Apr 17, 2024 1.19 0.01 0.85% 1.18 1.23 1.16
    Apr 16, 2024 1.16 0.02 1.75% 1.14 1.17 1.14
    Apr 15, 2024 1.11 -0.10 -8.26% 1.21 1.24 1.04
    Apr 12, 2024 1.19 -0.17 -12.50% 1.36 1.38 1.14
    Apr 11, 2024 1.41 0.13 10.16% 1.28 1.43 1.23
    Apr 10, 2024 1.27 0.00 0.00% 1.27 1.29 1.24
    Apr 9, 2024 1.27 -0.08 -5.93% 1.35 1.43 1.22
    Apr 8, 2024 1.39 0.05 3.73% 1.34 1.44 1.28
    Apr 5, 2024 1.32 -0.05 -3.65% 1.37 1.41 1.30
    Apr 4, 2024 1.34 -0.09 -6.29% 1.43 1.45 1.29
    Apr 3, 2024 1.40 0.05 3.70% 1.35 1.42 1.22
    Apr 2, 2024 1.30 -0.13 -9.09% 1.43 1.43 1.24
    Apr 1, 2024 1.45 -0.06 -3.97% 1.51 1.51 1.40
    Mar 28, 2024 1.52 0.03 2.01% 1.49 1.63 1.43
    Mar 27, 2024 1.48 -0.03 -1.99% 1.51 1.60 1.46
    Mar 26, 2024 1.49 0.05 3.47% 1.44 1.50 1.44
    Mar 25, 2024 1.45 -0.01 -0.68% 1.46 1.54 1.42
    Mar 22, 2024 1.41 -0.04 -2.76% 1.45 1.51 1.41
    Mar 21, 2024 1.44 0.04 2.86% 1.40 1.44 1.32

    DarioHealth Corp. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    12:30

    Country

    IL

    Event

    Q1 2024 DarioHealth Corp Earnings Release
    Q1 2024 DarioHealth Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 27.656 20.513 7.576 7.559 7.394
    Revenue 27.656 20.513 7.576 7.559 7.394
    Cost of Revenue, Total 18.001 16.55 5.063 4.962 5.629
    Gross Profit 9.655 3.963 2.513 2.597 1.765
    Total Operating Expense 88.931 97.007 37.479 25.264 25.082
    Selling/General/Admin. Expenses, Total 46.816 63.238 27.983 16.61 15.777
    Research & Development 19.649 17.219 4.433 3.692 3.676
    Unusual Expense (Income) 4.465
    Operating Income -61.275 -76.494 -29.903 -17.705 -17.688
    Interest Income (Expense), Net Non-Operating -0.107 -0.151 0.507 -0.004 -0.115
    Other, Net -0.807 -0.084 -0.049 -0.027
    Net Income Before Taxes -62.189 -76.729 -29.445 -17.736 -17.803
    Net Income After Taxes -62.193 -76.761 -29.445 -17.736 -17.803
    Net Income Before Extra. Items -62.193 -76.761 -29.445 -17.736 -17.803
    Net Income -62.193 -76.761 -29.445 -17.736 -17.803
    Total Adjustments to Net Income -1.643 -2.005 -3.658 -3.155 -0.493
    Income Available to Common Excl. Extra. Items -63.836 -78.766 -33.103 -20.891 -18.296
    Income Available to Common Incl. Extra. Items -63.836 -78.766 -33.103 -20.891 -18.296
    Diluted Net Income -63.836 -78.766 -33.103 -20.891 -18.296
    Diluted Weighted Average Shares 23.635 16.5917 5.96331 2.26614 1.17064
    Diluted EPS Excluding Extraordinary Items -2.70091 -4.74731 -5.55112 -9.21878 -15.629
    Diluted Normalized EPS -2.57811 -4.71283 -5.55112 -9.21878 -15.629
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 6.152 7.066 6.809 6.605 6.183
    Revenue 6.152 7.066 6.809 6.605 6.183
    Cost of Revenue, Total 4.078 3.898 4.077 4.805 5.045
    Gross Profit 2.074 3.168 2.732 1.8 1.138
    Total Operating Expense 23.839 19.263 19.155 22.316 23.529
    Selling/General/Admin. Expenses, Total 10.872 10.411 6.96 11.57 14.356
    Research & Development 5.222 5.165 4.782 4.803 4.137
    Operating Income -17.687 -12.197 -12.346 -15.711 -17.346
    Interest Income (Expense), Net Non-Operating 1.621 -0.579 -0.244 0.093 0.062
    Other, Net -0.519 -0.049 -0.024 -0.014 -0.743
    Net Income Before Taxes -16.585 -12.825 -12.614 -15.632 -18.027
    Net Income After Taxes -16.585 -12.825 -12.617 -15.632 -18.028
    Net Income Before Extra. Items -16.585 -12.825 -12.617 -15.632 -18.028
    Net Income -16.585 -12.825 -12.617 -15.632 -18.028
    Total Adjustments to Net Income -1.691 0 -0.265 -0.494 -0.433
    Income Available to Common Excl. Extra. Items -18.276 -12.825 -12.882 -16.126 -18.461
    Income Available to Common Incl. Extra. Items -18.276 -12.825 -12.882 -16.126 -18.461
    Diluted Net Income -18.276 -12.825 -12.882 -16.126 -18.461
    Diluted Weighted Average Shares 28.1863 27.57 25.911 22.9732 22.426
    Diluted EPS Excluding Extraordinary Items -0.6484 -0.46518 -0.49716 -0.70195 -0.8232
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.5183 -0.47283 -0.41348 -0.65241 -0.82346
    Unusual Expense (Income) 3.667 -0.211 3.336 1.138 -0.009
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 65.524 45.605 34.128 22.939 13.313
    Cash and Short Term Investments 49.522 36 28.777 20.586 11.177
    Cash & Equivalents 49.357 35.808 28.59 20.395 10.997
    Short Term Investments 0.165 0.192 0.187 0.191 0.18
    Total Receivables, Net 6.899 1.71 1.624 0.672 0.759
    Accounts Receivable - Trade, Net 6.416 1.31 0.124 0.672 0.168
    Total Inventory 7.956 6.228 2.293 1.414 1.377
    Prepaid Expenses 0.908 1.591 1.354 0.203
    Other Current Assets, Total 0.239 0.076 0.08 0.064
    Total Assets 119.191 100.771 35.407 24.569 14.089
    Property/Plant/Equipment, Total - Net 1.994 0.989 1.074 1.413 0.733
    Property/Plant/Equipment, Total - Gross 3.433 2.215 1.866 2.024
    Accumulated Depreciation, Total -1.439 -1.226 -0.792 -0.611
    Other Long Term Assets, Total 0.117 0.077 0.205 0.217 0.043
    Total Current Liabilities 19.35 14.376 7.034 5.22 5.164
    Accounts Payable 2.322 5.109 2.48 1.656 2.574
    Accrued Expenses 6.885 8.072 3.33 2.341
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.32 1.195 1.224 1.223 2.59
    Total Liabilities 39.192 15.222 7.256 5.675 5.164
    Total Long Term Debt 18.105 0 0 0 0
    Long Term Debt 18.105
    Other Liabilities, Total 1.737 0.846 0.222 0.455 0
    Total Equity 79.999 85.549 28.151 18.894 8.925
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.003 0.002 0.00081 0.00022 0.008
    Additional Paid-In Capital 365.846 307.561 171.399 129.039 98.171
    Retained Earnings (Accumulated Deficit) -285.85 -222.014 -143.248 -110.145 -89.254
    Total Liabilities & Shareholders’ Equity 119.191 100.771 35.407 24.569 14.089
    Total Common Shares Outstanding 25.7245 16.5734 8.11949 2.23565 1.83039
    Total Preferred Shares Outstanding 0.00357 0.01193 0.01582 0 0
    Other Equity, Total -0.00081 -0.00022
    Goodwill, Net 41.64 41.64
    Intangibles, Net 9.916 12.46
    Current Port. of LT Debt/Capital Leases 8.823
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 56.211 65.777 55.476 65.524 71.582
    Cash and Short Term Investments 44.273 52.995 43.318 49.522 57.257
    Cash & Equivalents 43.878 52.602 38.789 49.357 57.081
    Short Term Investments 0.395 0.393 4.529 0.165 0.176
    Total Receivables, Net 6.467 6.868 5.281 8.046 6.563
    Accounts Receivable - Trade, Net 4.533 4.821 2.797 6.416 4.521
    Total Inventory 5.471 5.914 6.877 7.956 7.762
    Total Assets 106.505 117.159 108.009 119.191 126.334
    Property/Plant/Equipment, Total - Net 1.977 1.888 1.935 1.994 2.032
    Goodwill, Net 41.64 41.64 41.64 41.64 41.64
    Intangibles, Net 6.541 7.678 8.803 9.916 11.053
    Other Long Term Assets, Total 0.136 0.176 0.155 0.117 0.027
    Total Current Liabilities 8.106 8.076 17.617 19.35 11.524
    Accounts Payable 1.929 1.451 1.883 2.322 1.982
    Accrued Expenses 0.119 0.145 0.291 0.293 0.27
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.684 0.789 0.925 1.32 2.76
    Total Liabilities 38.47 38.755 35.979 39.192 37.388
    Total Long Term Debt 29 29.094 16.745 18.105 24.046
    Other Liabilities, Total 1.364 1.585 1.617 1.737 1.818
    Total Equity 68.035 78.404 72.03 79.999 88.946
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.003 0.003 0.003 0.003 0.002
    Additional Paid-In Capital 401.887 395.352 370.702 365.846 361.912
    Retained Earnings (Accumulated Deficit) -333.855 -316.951 -298.675 -285.85 -272.968
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 106.505 117.159 108.009 119.191 126.334
    Total Common Shares Outstanding 27.2152 26.7847 25.8753 25.7245 23.291
    Total Preferred Shares Outstanding 0.01896 0.01896 0.00356 0.00357 0.00991
    Payable/Accrued 5.374 5.691 5.935 6.592 6.512
    Long Term Debt 29 29.094 16.745 18.105 24.046
    Current Port. of LT Debt/Capital Leases 0 8.583 8.823
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -62.193 -76.761 -29.445 -17.736 -17.803
    Cash From Operating Activities -47.845 -50.409 -17.736 -15.725 -11.47
    Cash From Operating Activities 0.356 0.282 0.19 0.183 0.207
    Non-Cash Items 20.108 26.322 11.369 2.625 3.758
    Changes in Working Capital -10.477 -3.287 0.15 -0.797 2.368
    Cash From Investing Activities -0.573 -8.134 -1.622 -0.113 0.006
    Capital Expenditures -0.573 -0.261 -0.118 -0.098 -0.071
    Other Investing Cash Flow Items, Total 0 -7.873 -1.504 -0.015 0.077
    Cash From Financing Activities 61.94 65.766 27.548 25.247 18.743
    Issuance (Retirement) of Stock, Net 38.154 65.766 27.548 25.247 18.743
    Net Change in Cash 13.522 7.223 8.19 9.409 7.279
    Amortization 4.361 3.035
    Cash Interest Paid 1.876
    Issuance (Retirement) of Debt, Net 23.786
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -12.825 -62.193 -49.576 -33.944 -15.916
    Cash From Operating Activities -4.757 -47.845 -39.904 -29.209 -18.094
    Cash From Operating Activities 0.097 0.356 0.243 0.154 0.07
    Amortization 1.113 4.361 3.224 2.087 0.963
    Non-Cash Items 4.585 20.108 13.818 9.303 5.35
    Changes in Working Capital 2.273 -10.477 -7.613 -6.809 -8.561
    Cash From Investing Activities -4.362 -0.573 -0.514 -0.34 -0.181
    Capital Expenditures -0.074 -0.573 -0.514 -0.34 -0.181
    Other Investing Cash Flow Items, Total -4.288 0 0 0 0
    Cash From Financing Activities -1.389 61.94 61.675 61.675 38.023
    Issuance (Retirement) of Stock, Net 38.154 37.889 37.889 38.023
    Net Change in Cash -10.508 13.522 21.257 32.126 19.748
    Cash Interest Paid 1.072 1.876 0.969 0.181
    Issuance (Retirement) of Debt, Net -1.389 23.786 23.786 23.786

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    DarioHealth Corp. Company profile

    About DarioHealth Corp

    DarioHealth Corp.(DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. DarioHealth products include Dario blood glucose monitoring, Dario Blood Pressure Monitoring System, and Dario Smart Scale. The Dario blood glucose monitoring device is a system that measure sugar levels. The Dario Smart Scale is a blood pressure monitoring system used to measure blood pressure and stored in a digital logbook in the Dario App. It offers modular platform integrating digital therapeutics, coaching, devices, and care providers. Its suite of offerings includes Dario Tools, DarioEngage, and Dario Loop.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, DarioHealth Corp revenues increased from $7.6M to $20.5M. Net loss applicable to common stockholders increased from $33.1M to $78.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Marketing and Pre-Production Cost increase from $12.5M to $33.7M (expense).

    Equity composition

    Common Stock $0.0001 Par, Shares auth. 45M and o/s 19,240,234 issd. Insiders own approx. 14.03% (after the IPO). If no information is provided, use TBA. 10/14 1-for-5 reverse stock split. 03/2016, 1-For-18 Reverse Stock Split.

    Industry: Medical Equipment, Supplies & Distribution (NEC)

    322 W 57Th St. #33B
    NEW YORK
    NEW YORK 10019
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    XRP/USD

    0.50 Price
    -2.090% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,236.50 Price
    -0.870% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    ETH/USD

    3,021.40 Price
    -1.640% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    62,700.15 Price
    -1.940% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading